Takahashi Ikuo, Kakeji Yoshihiro, Emi Yasunori, Sakurai Masato, Yonemura Yusuke, Kimura Yasue, Maehara Yoshihiko
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Gastric Cancer. 2003;6 Suppl 1:28-33. doi: 10.1007/s10120-003-0228-5.
S-1 (TS-1) is a novel oral anticancer drug. Because of the excellent results of phase II studies, we continued to prescribe S-1 for advanced or recurrent gastric cancer after we participated in the phase I and II studies.
Twenty-nine patients with advanced or recurrent gastric cancer were treated with S-1. Clinicopathological features, survival, and adverse reactions were analyzed.
One course of treatment consisted of 40, 50, or 60 mg/body twice a day for 28 days followed by withdrawal for 2 weeks. The mean number of treatments was 3.6 courses (range, 1-12 courses). The response rate was 37.9% (11 partial responses [PRs] in 29 patients). Although the response rate of patients who did not receive prior chemotherapy was 47.6% (10 PRs in 21 patients), that of patients with prior chemotherapy was 12.5% (1 PR in 8 patients). The median survival time was 14.1 months, and that of patients who responded to treatment was 22.1 months, which was significantly longer than that of nonresponder patients. One-year and 2-year survivals in the 29 patients were 50.2% and 24.3%, respectively. Adverse reactions were noted in 17 of 29 patients, and the most frequent one was leukocytopenia. Only 2 patients experienced grade 3 leukocytopenia and neutrocytopenia.
Because of the high response rate and low incidence of severe adverse reactions, S-1 is a first-line chemotherapy that can be used for outpatients, especially for patients without prior chemotherapy. As the response rate for patients with prior chemotherapy was low, combined therapy with S-1 is worth evaluating for these patients.
S-1（替吉奥）是一种新型口服抗癌药物。由于II期研究结果出色，我们在参与I期和II期研究后，继续为晚期或复发性胃癌患者开具S-1处方。
29例晚期或复发性胃癌患者接受S-1治疗。分析临床病理特征、生存率和不良反应。
一个疗程为每天两次，每次40、50或60mg/体，持续28天，随后停药2周。平均治疗疗程数为3.6个疗程（范围1 - 12个疗程）。缓解率为37.9%（29例患者中有11例部分缓解[PR]）。未接受过先前化疗的患者缓解率为47.6%（21例患者中有10例PR），而接受过先前化疗的患者缓解率为12.5%（8例患者中有1例PR）。中位生存时间为14.1个月，对治疗有反应的患者为22.1个月，明显长于无反应患者。29例患者的1年和2年生存率分别为50.2%和24.3%。29例患者中有17例出现不良反应，最常见的是白细胞减少。只有2例患者出现3级白细胞减少和中性粒细胞减少。
由于缓解率高且严重不良反应发生率低，S-1是一种可用于门诊患者的一线化疗药物，尤其适用于未接受过先前化疗的患者。由于接受过先前化疗的患者缓解率较低，S-1联合治疗对这些患者值得评估。
